Literature DB >> 21828144

Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice.

Kellie R Machlus1, Feng-Chang Lin, Alisa S Wolberg.   

Abstract

Studies have correlated elevated plasma factor VIII (FVIII) with thrombosis; however, it is unclear whether elevated FVIII is a proinflammatory biomarker, causative agent, or both. We raised FVIII levels in mice and measured the time to vessel occlusion (TTO) after ferric chloride-induced injury. Compared with control (saline-infused) mice, elevated FVIII had no effect after longer (3-minute) carotid artery injury, but it shortened the TTO after shorter (2-minute) injury (P < .008). After injury, circulating thrombin-antithrombin (TAT) complexes were lower after short versus long injury (P < .04), suggesting short treatment produced less coagulation activation. TAT levels in FVIII-infused mice were higher than in controls after short, but not longer, injury. Accordingly, elevated FVIII had no effect on in vitro thrombin generation or platelet aggregation triggered by high tissue factor, but it increased thrombin generation rate and peak (2.4- and 1.5-fold, respectively), and it accelerated platelet aggregation (up to 1.6-fold) when initiated by low tissue factor. Compared with control mice, elevated FVIII stabilized thrombi (fewer emboli) after short injury, but it had no effect after longer injury. TTO and emboli correlated with TATs. These results demonstrate dependence of FVIII activity on extent of vascular injury. We propose elevated plasma FVIII is an etiologic, prothrombotic agent after moderate but not extensive vascular damage.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21828144      PMCID: PMC3193271          DOI: 10.1182/blood-2011-06-362814

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Microplate coagulation assays.

Authors:  C W Pratt; D M Monroe
Journal:  Biotechniques       Date:  1992-09       Impact factor: 1.993

2.  Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system.

Authors:  G A Allen; A S Wolberg; J A Oliver; M Hoffman; H R Roberts; D M Monroe
Journal:  J Thromb Haemost       Date:  2004-03       Impact factor: 5.824

3.  Optimization, refinement and reduction of murine in vivo experiments to assess therapeutic approaches for haemophilia A.

Authors:  B Baumgartner; T Jaki; M J Wolfsegger; B Eder; A Schiviz; H P Schwarz; E M Muchitsch
Journal:  Lab Anim       Date:  2010-05-27       Impact factor: 2.471

4.  The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study.

Authors:  R P Tracy; A M Arnold; W Ettinger; L Fried; E Meilahn; P Savage
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-07       Impact factor: 8.311

5.  Haemostatic changes following surgery.

Authors:  C J Hawkey; Y Stirling; R Chakrabarti; M Brozovic; A G Cox; T W Meade
Journal:  Thromb Res       Date:  1983-10-15       Impact factor: 3.944

6.  Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice.

Authors:  X Wang; Q Cheng; L Xu; G Z Feuerstein; M-Y Hsu; P L Smith; D A Seiffert; W A Schumacher; M L Ogletree; D Gailani
Journal:  J Thromb Haemost       Date:  2005-02-23       Impact factor: 5.824

7.  Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.

Authors:  A Rumley; G D Lowe; P M Sweetnam; J W Yarnell; R P Ford
Journal:  Br J Haematol       Date:  1999-04       Impact factor: 6.998

8.  Characterization of von Willebrand factor in factor VIII concentrates.

Authors:  W A Fricke; M Y Yu
Journal:  Am J Hematol       Date:  1989-05       Impact factor: 10.047

9.  Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: A focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP).

Authors:  Beate Luxembourg; Joern Schmitt; Marek Humpich; Matthias Glowatzki; Dejan Dressler; Erhard Seifried; Edelgard Lindhoff-Last
Journal:  Thromb Haemost       Date:  2009-10       Impact factor: 5.249

10.  Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency.

Authors:  Niels Bovenschen; Joachim Herz; Jos M Grimbergen; Peter J Lenting; Louis M Havekes; Koen Mertens; Bart J M van Vlijmen
Journal:  Blood       Date:  2003-01-09       Impact factor: 22.113

View more
  14 in total

1.  Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.

Authors:  Bryce A Kerlin; Amanda P Waller; Ruchika Sharma; Melinda A Chanley; Marvin T Nieman; William E Smoyer
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

Review 2.  New findings on venous thrombogenesis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Hamostaseologie       Date:  2016-11-23       Impact factor: 1.778

Review 3.  Fibrinogen, red blood cells, and factor XIII in venous thrombosis.

Authors:  B L Walton; J R Byrnes; A S Wolberg
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

Review 4.  Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited.

Authors:  Alisa S Wolberg; Maria M Aleman; Karin Leiderman; Kellie R Machlus
Journal:  Anesth Analg       Date:  2011-11-21       Impact factor: 5.108

5.  A plasmin-activatable thrombin inhibitor reduces experimental thrombosis and assists experimental thrombolysis in murine models.

Authors:  W P Sheffield; L J Eltringham-Smith; S Gataiance; V Bhakta
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

Review 6.  Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation.

Authors:  Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-01       Impact factor: 4.733

7.  Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking.

Authors:  James R Byrnes; Cédric Duval; Yiming Wang; Caroline E Hansen; Byungwook Ahn; Micah J Mooberry; Martha A Clark; Jill M Johnsen; Susan T Lord; Wilbur A Lam; Joost C M Meijers; Heyu Ni; Robert A S Ariëns; Alisa S Wolberg
Journal:  Blood       Date:  2015-08-31       Impact factor: 22.113

8.  Elevated prothrombin promotes venous, but not arterial, thrombosis in mice.

Authors:  Maria M Aleman; Bethany L Walton; James R Byrnes; Jian-Guo Wang; Matthew J Heisler; Kellie R Machlus; Brian C Cooley; Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-30       Impact factor: 8.311

9.  In vitro and in vivo evaluation of the effect of elevated factor VIII on the thrombogenic process.

Authors:  M Golder; J Mewburn; D Lillicrap
Journal:  Thromb Haemost       Date:  2012-11-22       Impact factor: 5.249

Review 10.  Fibrinogen and factor XIII: newly recognized roles in venous thrombus formation and composition.

Authors:  Alisa S Wolberg
Journal:  Curr Opin Hematol       Date:  2018-09       Impact factor: 3.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.